Log In
Print
BCIQ
Print
Print this Print this
 

Lamivudine/zidovudine

  Manage Alerts
Collapse Summary General Information
Company Mylan N.V.
DescriptionFixed dose combination of 2 nucleoside analog reverse transcriptase inhibitors
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV/AIDS
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$40,100.0M

$20,050.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today